Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Yang, Wen Chi ^a,b   Tsai, Wan Chi ^b   Lin, Pai Mei ^c   Yang, Ming Yu ^d   Liu, Yi Chang ^a,e   Chang, Chao Sung ^a   Yu, Wen Hui ^a   Lin, Sheng Fung ^a,e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; BDH2; Cytogenetically normal acute myeloid leukemia; Prognosis; Survival; Survivin

Indexed keywords

2 HYDROXYBUTYRATE DEHYDROGENASE; CASPASE 3; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SURVIVIN; BDH2 PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; HYDROXYBUTYRATE DEHYDROGENASE; INHIBITOR OF APOPTOSIS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CYTOGENETICS; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; CELL LINE; CHINA; GENE EXPRESSION REGULATION; GENETICS; HL 60 CELL LINE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE; CHINA; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; HL-60 CELLS; HUMANS; HYDROXYBUTYRATE DEHYDROGENASE; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; YOUNG ADULT;

EID: 84884127295     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-58     Document Type: Article

References (42)

1. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Byrd JC, Mrozek K, Dodge RK, et al. Blood 2002 100 4325 4336 10.1182/blood-2002-03-0772 12393746 (Pubitemid 35429670)
2. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international report panel, on behalf of the European Leukemia Net. Dohner H, Estey EH, Amadori S, Appelbaum FR, et al. Blood 2010 115 453 474 10.1182/blood-2009-07-235358 19880497
3. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES, Blood 2011 117 19 5019 5032 10.1182/blood-2011-01-293050 21300984
4. KDH mutations in glioma and acute myeloid leukemia. Dang L, Jin S, Su SM, Trends Mol Med 2010 16 387 397 10.1016/j.molmed.2010.07.002 20692206
5. Mutation in TET2 in myeloid cancers. Delhommeau F, Dupont S, Della Valle V, et al. N Engl J Med 2009 360 2289 2301 10.1056/NEJMoa0810069 19474426
6. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML Study Group. Gaidzik VI, Bullinger L, Schlenk RF, et al. J Clin Oncol 2011 29 1364 1372 10.1200/JCO.2010.30.7926 21343560
7. Prognostic importance of MN1 transcript levels, and biologic insights from NM1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Langer C, Marcucci G, Holland KB, et al. J Clin Oncol 2009 27 3198 3204 10.1200/JCO.2008.20.6110 19451432
8. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Langer C, Radmacher MD, Ruppert AS, et al. Blood 2008 111 5371 5379 10.1182/blood-2007-11-124958 18378853
9. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Marcucci G, Maharry K, Whitman SP, et al. J Clin Oncol 2007 25 3337 3343 10.1200/JCO.2007.10.8720 17577018 (Pubitemid 47325620)
10. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Marcucci G, Maharry K, Wu YZ, et al. J Clin Oncol 2010 28 2348 2355 10.1200/JCO.2009.27.3730 20368543
11. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, NM1 and BAALC transcript levels using oligonucleotide microarrays. Metzeler KH, Dufour A, Benthaus T, et al. J Clin Oncol 2009 27 5031 5038 10.1200/JCO.2008.20.5328 19752345
12. TET2 mutations improve the new European Leukemia Net risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Metzeler KH, Maharry K, Radmacher MD, et al. J Clin Oncol 2011 29 10 1378 1381
13. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. Neubauer A, Maharry K, Mrozek K, et al. J Clin Oncol 2008 26 4603 4609 10.1200/JCO.2007.14.0418 18559876
14. Wilms tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Paschka P, Marcucci G, Ruppert AS, et al. J Clin Oncol 2008 26 4595 4602 10.1200/JCO.2007.15.2058 18559874
15. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Paschka P, Schlenk RF, Gaidzik VI, et al. J Clin Oncol 2010 28 3636 3643 10.1200/JCO.2010.28.3762 20567020
16. AML1/RUNX1 mutations in 470 adults patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Tang JL, Hou HA, Chen CY, et al. Blood 2009 114 5352 5361 10.1182/blood-2009-05- 223784 19808697
17. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. Mithat Gönen JP, Figueroa ME, Fernandez H, et al. New Eng J Med 2012 366 1079 1089 10.1056/NEJMoa1112304 22417203
18. On the origin of cancer cells. Warburg O, Science 1956 123 309 314 10.1126/science.123.3191.309 13298683
19. Understanding the Warbur effect: The metabolic requirements of cell proliferation. Vander Heiden MG, Cantley LC, Thompson CB, Science 2009 324 1029 1033 10.1126/science.1160809 19460998
20. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Luo J, Manning BD, Cantley LC, Cancer Cell 2003 4 257 262 10.1016/S1535-6108(03) 00248-4 14585353 (Pubitemid 37329790)
21. Characterization of human DHRS6, an orphan short chain dehydrogenase/reductase enzyme: a novel, cytosolic type 2 R-beta-hydroxybutyrate dehydrogenase. Guo K, Lukacik P, Papagrigoriou E, et al. J Biol Chem 2006 281 10291 10297 10.1074/jbc.M511346200 16380372 (Pubitemid 43864567)
22. A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Devireddy LR, Hart DO, Goetz DH, Green MR, Cell 2010 141 1006 1017 10.1016/j.cell.2010.04.040 20550936
23. Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Yang WC, Lin PM, Yang MY, et al. Leukemia Lymphoma 2012 10.3109/10428194.2012.749402
24. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Schnittger S, Kinkelin U, Schoch C, et al. Leukemia 2000 14 796 804 10.1038/sj.leu.2401773 10803509 (Pubitemid 30235055)
25. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. Falini B, Mecucci C, Tiacci E, et al. N Engl J Med 2005 352 254 266 10.1056/NEJMoa041974 15659725 (Pubitemid 40110814)
26. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Kiyoi H, Naoe T, Nakano Y, et al. Blood 1999 93 3074 3080 10216104 (Pubitemid 29200800)
27. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Pabst T, Mueller BU, Zhang P, et al. Nat Genet 2001 27 263 270 10.1038/85820 11242107 (Pubitemid 32201846)
28. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the the isocitrate dehydrogenase 1 mutation. Chou WC, Hou HA, Chen CY, et al. Blood 2010 115 2749 2754 10.1182/blood-2009-11-253070 20097881
29. Role of reactive oxygen species (ROS) in apoptosis induction. Simon HU, Haj-Yehia A, Levi-Schaffer F, Apoptosis 2000 5 415 418 10.1023/A:1009616228304 11256882 (Pubitemid 32162623)
30. Survivin mediates self-protection through ROS/cdc25c/CDK1 signaling pathway during tumor cell apoptosis induced by high fluence low-power laser irradiation. Chu J, Wu S, Xing D, Cancer Lett 2010 297 207 219 10.1016/j.canlet.2010.05.013 20579806
31. Survivin mediates the anti-apoptotic effect of delta-opioid receptor stimulation in cardiomyocytes. Yao LL, Wang YG, Cai WJ, Yao T, Zhu YC, J Cell Sci 2007 120 895 907 10.1242/jcs.03393 17298978 (Pubitemid 46523491)
32. Ketone Bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Laffel L, Diabetes Metab Res Rev 1999 15 412 426 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8 10634967 (Pubitemid 30066228)
33. The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. Pavlides S, Tsirigos A, Mibneco G, et al. Cell Cycle 2010 9 3485 3505 10.4161/cc.9.17.12721 20861672
34. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. Maurer GD, Brucker DP, Bahr O, et al. BMC Cancer 2011 11 315 321 10.1186/1471-2407-11-315 21791085
35. Trigg, MD, Anne Flanigan-Minnick: Mechanisms of action of commonly used drugs to treat cancer (Review). Michael E, Comm Oncol 2011 8 357 369 10.1016/S1548-5315(12)70051-7
36. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Müller I, Niethammer D, Bruchelt G, Int J Mol Med 1998 1 491 494 9852255
37. The Bcl2 family: regulators of the cellular life-or-death switch. Cory S, Adams JM, Nat Rev Cancer 2002 2 647 656 12209154 (Pubitemid 37328916)
38. Mechanisms of caspase activation and inhibition during apoptosis. Shi Y, Mol Cell 2002 9 459 470 10.1016/S1097-2765(02)00482-3 11931755 (Pubitemid 34273778)
39. An IAP-IAP complex inhibits apoptosis. Dohi T, Okada K, Xia F, et al. J Biol Chem 2004 279 34087 34090 10.1074/jbc.C400236200 15218035 (Pubitemid 39318028)
40. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Mita AC, Mita MM, Nawrocki ST, Giles FJ, Clin Cancer Res 2008 14 5000 5005 10.1158/1078-0432.CCR-08-0746 18698017
41. The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL by regulating the antiapoptotic protein Bcl-xL. Bansal H, Seifert T, Bachier C, et al. J Biol Chem 2012 287 39 32875 32880 10.1074/jbc.C112.366559 22898820
42. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Blood 2012 119 5824 5831 10.1182/blood-2011-07-367961 22490330